Veradigm Stock Price, News & Analysis

Veradigm Inc. (NASDAQ: MDRX) has approved a new share repurchase program allowing it to buy back up to $250 million of its common stock, replacing the previous program which was nearly fully used in 2022. The company repurchased $57 million in Q4 2022 for a total of $234 million for the year. Additionally, Veradigm provided initial financial guidance for Fiscal 2023, projecting revenue between $640 million and $660 million and non-GAAP EPS between $0.90 and $1.00.

Veradigm Inc. (NASDAQ: MDRX) announced robust fourth quarter performance, adding significant new business across payer, life science, and provider markets. The Payer segment grew by 26% annually, adding 6 new clients. In the Provider market, there was a remarkable 200% year-over-year increase in revenue cycle management clients, totaling 30 new clients. Moreover, Veradigm Life Science signed over 20 agreements in Q4, leveraging its de-identified patient dataset. The company aims to enhance interoperability and integration to improve healthcare outcomes.

Veradigm Inc. (NASDAQ: MDRX) has announced a significant investment in Holmusk, contributing to its $45 million series B financing round. This partnership aims to enhance Holmusk's NeuroBlu Database, a vital resource for real-world clinical behavioral health data. Veradigm will also collaborate with Holmusk to integrate de-identified patient data into this database.

CEO Rick Poulton emphasized the importance of addressing mental health issues exacerbated by the COVID-19 pandemic. This collaboration positions Veradigm as a key player in advancing behavioral health solutions.

Veradigm Inc. (Nasdaq:MDRX), formerly Allscripts Healthcare Solutions, announced that CEO Rick Poulton will present at the 2023 J.P. Morgan Healthcare Conference on January 11, 2023, at 3:45 PM PST. The live audio webcast will be available, along with a replay, accessible via the J.P. Morgan link. Veradigm is committed to transforming healthcare through innovative technology and data solutions.

Allscripts Healthcare Solutions, Inc. has officially rebranded to Veradigm Inc. (NASDAQ: MDRX) effective January 1, 2023. This transition marks the culmination of a two-year effort to align its solutions with the Veradigm brand. The Veradigm Network connects over 300,000 healthcare providers and represents more than 170 million patients, focusing on interoperable solutions that enhance patient care. The change aims to position Veradigm as a leader in value-based care, integrating all previous Allscripts assets into one cohesive network.

Sphere announced the integration of its TrustCommerce platform with Veradigm Practice Management (formerly Allscripts) on November 30, 2022. This integration allows healthcare providers to accept and post payments in real-time, enhancing staff efficiency and reducing errors. Key benefits include automated payment processes, improved security through encrypted transactions, and ongoing customer support. The collaboration aims to streamline the patient financial experience and optimize operational performance for healthcare providers.

Veradigm, a business unit of Allscripts (NASDAQ: MDRX), has joined The Point of Care Marketing Association (POCMA) as its first EHR marketing solution member. Stuart Green, Veradigm's Senior VP & General Manager, has joined POCMA's board of directors. The POCMA advocates for the effective use of point of care communication to improve patient healthcare outcomes. Veradigm aims to leverage this membership to enhance awareness of innovative marketing channels and contribute to industry best practices.

Allscripts announced that its business unit, Veradigm, received the 2015 ONC Health IT Update Certification for its EHR platform. This certification confirms that Veradigm EHR complies with federal reporting requirements and the latest 21st Century Cures Act regulations, ensuring eligible clinicians can participate in quality programs. Veradigm EHR aims to support independent physician practices with advanced technology, improving patient care and practice profitability. Allscripts aims to enhance healthcare outcomes through its integrated solutions.

Allscripts Healthcare Solutions (MDRX) reported third quarter 2022 consolidated revenue of $152 million, a 4.8% increase from $145 million in Q3 2021. Veradigm revenue reached $145 million, up from $137 million year-over-year. Operating profit rose over 30% to $25 million, though GAAP net income dipped slightly to $15 million from $16 million. Non-GAAP diluted earnings per share were $0.23, up from $0.21 in the prior year. The company affirms a 2022 outlook with Veradigm revenue growth expected between 6% to 7% and free cash flow forecasted at $110 million to $120 million.